Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Search stocks
Jagsonpal Pharmaceuticals Ltd

| Quarterly Financial Results Q3 FY 2025–26

NEUTRAL SENTIMENT

Report Source

⬤21st Jan 26

Summary : Jagsonpal Pharmaceuticals reported unaudited Q3 and 9M 2025 results, including a strategic acquisition, factory disposal, and ongoing tax dispute, with a clean auditor's review.

Quarterly Report Analysis & Insights

Financial Disclosures

  1. Cost of materials consumed: 39.51 million (Q3 2025).
  2. Purchases of stock-in-trade: 228.13 million (Q3 2025).
  3. Employee benefits expense: 172.95 million (Q3 2025).
  4. Other expenses: 126.45 million (Q3 2025).
  5. Revenue from operations: 729.45 million (Q3 2025), 2,230.22 million (9M 2025).
  6. Other income: 29.75 million (Q3 2025), 88.27 million (9M 2025).
  7. SGST demand of 15.20 million, company plans to appeal.
  8. Paid-up equity share capital: 133.57 million (Dec 2025).
  9. Reserves (other equity): 2,266.70 million (March 2025).
  10. Unaudited financial results are for Jagsonpal Pharmaceuticals Limited (standalone).

Corporate Overview

  1. Serves customers in India and overseas.
  2. Impact of new Labour Codes on employee benefits.
  3. SGST order demanding 15.20 million payment.
  4. Primarily engaged in manufacturing and trading of pharmaceutical products.
  5. Includes active pharmaceutical ingredients (APIs).
  6. Formal and factual reporting of financial results.
  7. Considered a single reportable business segment.
  8. Acquired India and Bhutan business of Yash Pharma Laboratories Private Limited.
  9. Acquisition broadens presence in dermatology and childcare products.

Risk Factors

  1. New Labour Codes impact employee benefit expenses.
  2. SGST order demands 15.20 million payment.
  3. Ongoing appeal against tax demand order.

Key Drivers

  1. Acquired Yash Pharma's India and Bhutan business.
  2. Broadens market presence in Indian dermatology.
  3. Employees exercised vested stock options.

Auditor’s Report

  1. Clean limited review conclusion; no material misstatement found.

Board Commentary

  1. Additional employee benefit expense due to new Labour Codes.
  2. Potential financial impact from SGST demand order.
  3. Impact of new Labour Codes on employee benefits.
  4. SGST order for 15.20 million related to Input Tax Credit mismatches.
  5. Acquisition of Yash Pharma's India and Bhutan business for 940.12 million.
  6. Termination of Business Transfer Agreement for Resilient Cosme-Ceuticals divisions.
  7. Disposed of Faridabad factory premises for 410 million.

Corporate Governance

  1. Audit Committee reviewed financial results.

Management Discussion & Analysis

Future Strategy

  1. Strategic goal to broaden presence in the Indian market.

Risk Control Measures

  1. Monitoring further notifications and rules under new Labour Codes.
  2. Company believes SGST case has merits and will appeal.

Critical Risks

  1. Changes in employee benefit computation due to new Labour Codes.
  2. Demand from SGST order for financial year 2021-22.
Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) Quarterly Report Analysis & Insights | Dhanarthi